The arc of biotechnology is one of breakthroughs and struggles, writes Tim Hunt, CEO of the Alliance for Regenerative ...

Q4 2024 Management View Walter Klemp, Chairman and CEO, announced significant progress on the MIRACLE Phase 3 pivotal trial for Annamycin, targeting second-line treatment of relapsed and refractory ...

despite acknowledging Xencor's pipeline progress. The divergence in analyst views underscores the speculative nature of biotechnology investments and the importance of upcoming clinical data in ...

ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation and Industry MomentumSARASOTA, Fla.

PASADENA, Calif, March 27, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE” or the "Company”) (Nasdaq: ...

THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

Hello, and welcome to the Moleculin Biotech fourth quarter and full year 2024 update conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded. At this time ...

Heltzen expressed excitement for the event, emphasizing the company's progress in advancing sustainable biotechnology through their innovative AI-engineered enzymes, known as exozymes, which aim ...

their progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends ...

Supreme Court hearings on GM crops progress, DBT supports GM mustard, BioE3 policy focus, bio-agriculture growth in India.

Oncolytics (ONCY) reported on progress in 2025 with key regulatory ... Hot Stocks on TipRanks >> Read More on ONCY: Oncolytics Biotech NewsMORE Related Stocks Indices Commodities Currencies ...